GSK PHARMA 2018-19 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA 2018-19 Annual Report Analysis
Mon, 24 Jun

GSK PHARMA has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

GSK PHARMA Income Statement Analysis

  • Operating income during the year rose 8.9% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 18.8% YoY during the fiscal. Operating profit margins witnessed a fall and down at 19.2% in FY19 as against 17.6% in FY18.
  • Depreciation charges increased by 27.9% and finance costs increased by 200.0% YoY, respectively.
  • Other income grew by 87.6% YoY.
  • Net profit for the year grew by 27.0% YoY.
  • Net profit margins during the year grew from 12.0% in FY18 to 13.8% in FY19.

GSK PHARMA Income Statement 2018-19

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Net Sales Rs m 28,715 31,281 8.9%
Other income Rs m 545 1,023 87.6%
Total Revenues Rs m 29,260 32,304 10.4%
Gross profit Rs m 5,059 6,009 18.8%
Depreciation Rs m 380 486 27.9%
Interest Rs m 2 6 200.0%
Profit before tax Rs m 5,222 6,540 25.2%
Tax Rs m 1,892 2,373 25.4%
Profit after tax Rs m 3,508 4,454 27.0%
Gross profit margin % 17.6 19.2
Effective tax rate % 36.2 36.3
Net profit margin % 12.0 13.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



GSK PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY19 down at Rs 15 billion as compared to Rs 16 billion in FY18, thereby witnessing an decrease of -9.1%.
  • Long-term debt down at Rs 2 million as compared to Rs 6 million during FY18, a fall of 66.7%.
  • Current assets fell 8% and stood at Rs 20 billion, while fixed assets rose 15% and stood at Rs 14 billion in FY19.
  • Overall, the total assets and liabilities for FY19 stood at Rs 39 billion as against Rs 39 billion during FY18, thereby witnessing a fall of 1%.

GSK PHARMA Balance Sheet as on March 2019

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Networth Rs m 20,573 21,398 4.0
 
Current Liabilities Rs m 15,999 14,543 -9.1
Long-term Debt Rs m 6 2 -66.7
Total Liabilities Rs m 39,475 39,113 -0.9
 
Current assets Rs m 21,815 20,061 -8.0
Fixed Assets Rs m 12,475 14,343 15.0
Total Assets Rs m 39,475 39,113 -0.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



GSK PHARMA Cash Flow Statement Analysis

  • GSK PHARMA's cash flow from operating activities (CFO) during FY19 stood at Rs 4 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY19 stood at Rs -1 billion, an improvement of 37.6% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY19 stood at Rs -4 billion on a YoY basis.
  • Overall, net cash flows for the company during FY19 stood at Rs -1 billion from the Rs 620 million net cash flows seen during FY18.

GSK PHARMA Cash Flow Statement 2018-19

Particulars No. of months 12 12 % Change
Year Ending Mar-18 Mar-19
Cash Flow from Operating Activities Rs m 4,728 3,994 -15.5%
Cash Flow from Investing Activities Rs m -1,042 -1,433 -
Cash Flow from Financing Activities Rs m -3,066 -3,584 -
Net Cash Flow Rs m 620 -1,023 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for GSK PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 26.3, an decline from the EPS of Rs 41.4 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 1,231.5, stands at 49.0 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 19.2 times, while the price to sales ratio stands at 13.1 times.
  • The company's price to cash flow (P/CF) ratio stood at 42.2 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Sales per share (Unadj.) Rs 339.0 184.7
TTM Earnings per share Rs 41.4 26.3
Diluted earnings per share Rs 20.7 26.3
Price to Cash Flow x 26.8 42.2
TTM P/E ratio x 24.5 49.0
Price / Book Value ratio x 9.9 19.2
Market Cap Rs m 104,308 208,623
Dividends per share (Unadj.) Rs 35.0 20.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for GSK PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.4x during FY19, from 1.4x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 1,091.0x during FY19, from 2,612.0x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 20.8% during FY19, from 17.1% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 31.9% during FY19, from 26.2% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 11.4% during FY19, from 8.9% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Current ratio x 1.4 1.4
Debtors’ Days Days 19 14
Interest coverage x 2,612.0 1,091.0
Debt to equity ratio x 0.0 0.0
Return on assets % 8.9 11.4
Return on equity % 17.1 20.8
Return on capital employed % 26.2 31.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how GSK PHARMA has performed over the last 5 years, please visit here.

GSK PHARMA Share Price Performance

Over the last one year, GSK PHARMA share price has moved up from Rs 1,400.5 to Rs 1,231.5, registering a loss of Rs 169.0 or around 12.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,651.9 (down 0.3%). Over the last one year it has moved down from 14,298.5 to 12,651.9, a loss of 1,647 points (down 11.5%).

Overall, the S&P BSE SENSEX is up 10.4% over the year.

(To know more, check out historical annual results for GSK PHARMA and quarterly results for GSK PHARMA)

Equitymaster requests your view! Post a comment on "GSK PHARMA 2018-19 Annual Report Analysis". Click here!

  

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS